| __timestamp | BioCryst Pharmaceuticals, Inc. | Gilead Sciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 122000 | 3788000000 |
| Thursday, January 1, 2015 | 1896000 | 4006000000 |
| Friday, January 1, 2016 | 2699000 | 4261000000 |
| Sunday, January 1, 2017 | 1702000 | 4371000000 |
| Monday, January 1, 2018 | 471000 | 4853000000 |
| Tuesday, January 1, 2019 | 4101000 | 4675000000 |
| Wednesday, January 1, 2020 | 1676000 | 4572000000 |
| Friday, January 1, 2021 | 7264000 | 6601000000 |
| Saturday, January 1, 2022 | 6594000 | 5657000000 |
| Sunday, January 1, 2023 | 4661000 | 6498000000 |
| Monday, January 1, 2024 | 28675800000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, cost efficiency is a critical factor for success. This analysis compares the cost of revenue efficiency between Gilead Sciences, Inc. and BioCryst Pharmaceuticals, Inc. over the past decade. Gilead Sciences, a leader in antiviral drugs, consistently demonstrates robust cost management, with an average cost of revenue around $4.9 billion annually. In contrast, BioCryst Pharmaceuticals, known for its innovative treatments for rare diseases, operates on a much smaller scale, with costs averaging just over $3 million per year.
From 2014 to 2023, Gilead's cost of revenue peaked in 2021, reaching approximately $6.6 billion, while BioCryst saw its highest cost in the same year at $7.3 million. Despite the vast difference in scale, both companies show a commitment to optimizing their cost structures, reflecting their strategic priorities in the biotech industry.
Cost of Revenue Comparison: AbbVie Inc. vs Gilead Sciences, Inc.
Cost of Revenue Comparison: AstraZeneca PLC vs BioCryst Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Amgen Inc. vs Gilead Sciences, Inc.
Cost of Revenue: Key Insights for Gilead Sciences, Inc. and Intra-Cellular Therapies, Inc.
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Alkermes plc
Cost Insights: Breaking Down Gilead Sciences, Inc. and Wave Life Sciences Ltd.'s Expenses
Cost of Revenue: Key Insights for Gilead Sciences, Inc. and Iovance Biotherapeutics, Inc.
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Travere Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Teva Pharmaceutical Industries Limited vs BioCryst Pharmaceuticals, Inc.
Cytokinetics, Incorporated vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Geron Corporation and BioCryst Pharmaceuticals, Inc.'s Expenses
Cost of Revenue: Key Insights for Amphastar Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.